Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
Volume 0.07M
Average 0.62M
EDSA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Edesa Biotech, Inc.NASDAQ: EDSA
Stock-Based Compensation · Q2 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q2 FY2026 stock-based compensation of $66.65K rose 0.0% year over year, behind the +113.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 17.9% from the prior quarter. Over 3 fiscal years it compounded at -31.4% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +113.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 729.64K USD
- Year-over-year change
- +35.7%
- 4-year CAGR
- -30.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 729.64K | +35.7% |
| FY2024 | 2024-09-30 | 537.49K | -56.9% |
| FY2023 | 2023-09-30 | 1.25M | -44.9% |
| FY2022 | 2022-09-30 | 2.26M | -29.3% |
| FY2021 | 2021-09-30 | 3.2M | — |
Stock-Based Compensation vs competitors
How EDSA compares with its peers on the latest reported figures
- EDSA's LTM Mar 2026 stock-based compensation of $729.64K is the largest of the 2 companies compared; the peer median is $271.17K.
- Its year-over-year change of +113.5% is the highest of 2, against a peer median of -35.7%.
- Over three fiscal years its annual growth of -31.4% compares with a peer median of -15.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $729.64K | +113.5% | -31.4% | — | |
| LTM Mar 2026 | $271.17K | -35.7% | -15.2% | — | |
| Peer median (excluding EDSA) | $271.17K | -35.7% | -15.2% | — | |
Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.19M) |
| Depreciation & Amortization | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| Deferred Income Tax | (3.31M) | (2.38M) | (308K) | 0 | 0 |
| Stock-Based Compensation | 3.2M | 2.26M | 1.25M | 537.49K | 729.64K |
| Change in Working Capital | (3.64M) | 2.89M | 308K | 571.07K | (985.65K) |
| Accounts Receivables | (3.23M) | 2.03B | 562.77K | 356.34K | (377.99K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (124.72K) | 882.84K | (556.27K) | 0 | 0 |
| Other Working Capital | (281.36K) | (2.03B) | 301.5K | 214.73K | (607.67K) |
| Other Non-Cash Items | 3.31M | 2.38M | 308K | (14.77K) | 0 |
| Operating Cash Flow | (13.66M) | (12.28M) | (6.64M) | (4.89M) | (7.32M) |
| Capital Expenditures | (6.15K) | (5.66K) | 3 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (3) | 0 | 0 |
| Investing Cash Flow | (6.15K) | (5.66K) | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | (29.53K) | 0 |
| Common Stock Issued | 14.17M | 11.63M | 4.83M | 621.56K | 17.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 14.17M | 11.63M | 4.83M | 592.03K | 17.03M |
| Effect of Forex Changes | 121.9K | (93.01K) | 76.85K | (25.9K) | 46.22K |
| Net Change in Cash | 625.56K | (748.34K) | (1.73M) | (4.32M) | 9.75M |
| Free Cash Flow | (13.67M) | (12.28M) | (6.64M) | (4.89M) | (7.32M) |
Edesa Biotech, Inc.
NASDAQ:EDSA
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.